PROVO, Utah--(BUSINESS WIRE)----The scientific and medical community took notice when it was recently announced that the world's
leading expert on L-arginine had licensed her patented product to Synergy Worldwide, a Nutraceutical company in Provo, Utah.
The L-arginine patent is the brainchild of world-renowned researcher, Dr. Ann de Wees Allen, Chief of Biomedical Research at the Glycemic Research
Institute in Washington, D.C.
After 20 years of research on L-arginine, it was assumed that Dr. Allen would license her patent to a large Pharmaceutical company. Corporate and
Pharmaceutical negotiations for the rights to the patent came to an abrupt halt when the decision was announced that Synergy Worldwide had been
granted the rights to the L-arginine patent.
Dr. Allen's L-arginine patent is considered the breakthrough product of the Century, and is currently valued at over 100 million dollars.
The value of the patent was based on the unique properties of Dr. Allen's formula.
Since the Nobel Prize was awarded for Nitric Oxide/L-arginine, the Pharmaceutical and Nutraceutical industries have rushed to bring
L-arginine products to market. According to scientists, the problem is that no-one appears to know enough about L-arginine to produce a product that is both
efficacious and safe for human use. Though L-arginine has been shown, in over 10,000 clinical studies, to provide health benefits to humans, the process
for eliminating side effects has eluded formulators. Additionally, the major benefit of L-arginine appears to be the reactivation of anti-aging
mechanisms, but the action required is complex, and takes precise formulating.
Dr. Allen states, "You cannot simply place L-arginine in a capsule or spray, or in a formula that does not contain the proper co-factors, and expect it
to work. That won't happen. L-arginine is both dose-dependent and timing-dependent, and it is very selective about crossing the
blood-brain-barrier, where it releases anti-aging-hormones."
Researchers agree that L-arginine formulas containing Lysine, sucrose, maltodextrins, and any other competing agent, does not work. L-arginine
also reactivates the herpes simplex virus (HSV), and produces nitric oxide (NO), which can cause severe free radical damage. The methodology
utilized in producing an L-arginine product that does not carry these side effects was developed by Dr. Allen.
When reporters asked Dr. Allen and Synergy Worldwide to reveal these processes to the medical and scientific community, they declined, stating
that the process is "proprietary, and not described in the patent." One of the processing secrets that has been disclosed by
chemists working on the project, is the extraction of organic Kiwi glycosides and low glycemic carbohydrates that are then bound to L-arginine molecules.
Synergy Worldwide announced that the name of the L-arginine product will be
PROARGI-9, to be launched mid-February 2004
Click here to
see Wall
Street's reaction to this news
